07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

Cebranopadol: Phase III data

The double-blind, international Phase III CORAL trial in 125 patients with moderate to severe chronic cancer pain currently on opioid treatment showed that once-daily oral cebranopadol met the primary endpoint of non-inferiority to twice-daily oral...
07:00 , Sep 22, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: prepronociceptin (PNOC; NOP); μ opioid receptor (MOR; OPRM1)

Neurology INDICATION: Pain Monkey studies suggest a dual MOR/ PNOC agonist could help treat pain. In monkey models of thermal nociception and allodynia, a subcutaneous 0.01 mg/kg dose of an orvinol-based MOR/PNOC agonist decreased pain...
07:00 , Apr 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: κ opioid receptor (KOR; OPRK1); µ opioid receptor (MOR; OPRM1); opioid receptor δ1 (OPRD1; DOR); prepronociceptin (PNOC; NOP)

Neurology INDICATION: Pain; diabetic neuropathy In vitro, mouse and rat studies identified two agonists of KOR , MOR and OPRD1 and antagonists of PNOC that could help treat neuropathic pain and diabetic neuropathy. Chemical synthesis...
08:00 , Dec 20, 2000 |  BC Extra  |  Politics & Policy

Final U.S. organic food standards released

U.S. Agriculture Secretary Dan Glickman on Wednesday released final national standards for organic foods. The standards specifically exclude the use of genetic engineering methods in foods labeled as organic. The Department of Agriculture excluded biotech...
08:00 , Mar 13, 2000 |  BioCentury  |  Politics, Policy & Law

U.K. OKs GMO trials

Full-scale trials of three GM crops across England and Wales have been given the go ahead after enough farmers were recruited to conduct the tests. On Friday, an independent committee of scientists agreed that 15...